VX 702
Alternative Names: KVK-702; VX-702Latest Information Update: 27 May 2010
At a glance
- Originator Vertex Pharmaceuticals
- Developer Kissei Pharmaceutical; Vertex Pharmaceuticals
- Class Anti-inflammatories; Antirheumatics; Phenylurea compounds
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute coronary syndromes; Cardiovascular disorders; Rheumatoid arthritis
Most Recent Events
- 31 Mar 2009 No development reported - Phase-I for Rheumatoid arthritis in Japan (PO)
- 31 Mar 2009 No development reported - Phase-II for Rheumatoid arthritis in Europe (PO)
- 14 Jun 2008 Pooled efficacy, pharmcaodynamic and safety data from two phase II trials in Rheumatoid arthritis presented at the Annual European Congress of Rheumatology (EULAR-2008)